90/013,682OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN7,700,567Closed

Status

Reexamination Certificate Issued

Filed

Jan 19, 2016

Last Updated

Jun 24, 2016

Art Unit

3991

Requester (Patent Owner)Inferred

AsteX Pharmaceuticals Inc.

Requested By

Patent Owner

Sector (CPC)

ALife Sciences & Consumer
A61Medical & Pharmaceutical
A61KPharmaceutical Preparations

USPC

514Drug, Bio-Affecting And Body Treating Compositions

Reexam History (28 events)

Jun 25, 2016CCRDYApplication ready for PDX access by participating foreign offices
Jun 24, 2016REEXInput Issue Number and Issue Date for Reexamination
Jun 16, 2016RXPUBSReexam Forwarded to Office of Publications
Jun 9, 2016MRNRCRX - Mail Notice of Intent to Issue a Reexam Certificate
Jun 8, 2016MREXNRX - Mail Examiner Interview Summary Record
May 13, 2016RXA...Response after Non-Final Action
Mar 16, 2016MR.NFRX - Mail Reexam Non-Final Action
Mar 15, 2016NRX.Notice of Reexam Published in Official Gazette
Feb 17, 2016MREXORX - Mail Ex Parte Request for Reexamination Granted
Feb 9, 2016IDSCInformation Disclosure Statement considered
Feb 3, 2016CRFECRF Is Good Technically / Entered into Database
Feb 1, 2016DOCKCase Docketed to Examiner in GAU
Jan 27, 2016MRPWPRX - Mail Pilot Waiver Program - Ex Parte Interview Summary
Jan 26, 2016RXWVSTWaiver of owners statement in ex parte
Jan 22, 2016MRXNReexamination Formalities Notice Mailed
Jan 22, 2016MRXNReexamination Formalities Notice Mailed
Jan 21, 2016RXTTLRPTTitle Report
Jan 21, 2016RXPCOMCompletion of Preprocessing - Released to Assigned GAU
Jan 21, 2016RXNREQFDNotice of reexamination request filing date
Jan 21, 2016RXNREQAUNotice of assignment of reexamination request
Jan 21, 2016FTFIFITF set to NO - revise initial setting
Jan 20, 2016RXLITSRReexam Litigation Search Conducted
Jan 19, 2016WIDSInformation Disclosure Statement (IDS) Filed
Jan 19, 2016RXOSUB.RReexamination requested by third party requester
Jan 19, 2016RXOSUBReceipt of Original Ex Parte Reexam Request
Jan 19, 2016RXIDS.Information Disclosure Statement Filed
Jan 19, 2016RXA.PEPre-Examination Amendment
Jan 19, 2016BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)

Prosecution, PTAB & CAFC

PTAB Proceedings (IPR, PGR, CBM, DER)

None found

Federal Circuit (CAFC)

None found

Terminal Disclaimer

None found

Prosecution History

None found

Maintenance Fees

Grant
Apr 20, 2010
3.5-yr
Oct 20, 2013
7.5-yr
Oct 20, 2017
Paid Oct 20, 2017
11.5-yr
Oct 20, 2021
Paid Oct 20, 2021
Expiry
Sep 29, 2025

Entity Status

Large Entity

Expires

Sep 29, 2025 (expired)

Assignments

20062007200820092010201120122013201420152016FiledPASIT PHIASIVONGSASANJEEV REDKARSUPERGEN, INC.ASTEX PHARMACEUTICALS, INC.ASTEX PHARMACEUTICALS, INC.
AssignmentReel/Frame: 017317/0253Recorded: Dec 1, 2005

From

PASIT PHIASIVONGSAInventor
Nov 3, 2005
SANJEEV REDKARInventor
Nov 3, 2005

To

SUPERGEN, INC.

Name ChangeReel/Frame: 029625/0444Recorded: Jan 14, 2013

From

SUPERGEN, INC.
Sep 9, 2011

To

ASTEX PHARMACEUTICALS, INC.

OtherReel/Frame: 037569/0034Recorded: Jan 21, 2016

From

ASTEX PHARMACEUTICALS, INC.
Jan 21, 2016

To

ASTEX PHARMACEUTICALS, INC.